Breaking news

Gold’s Gleam: Caution Amid The Rally

Gold prices are surging, with the SPDR Gold Shares (GLD) fund up about 11% in 2025 and returns climbing roughly 42% over the past year. Gold futures, too, are on the rise—up around 10% year-to-date and 36% higher than last year. By contrast, the S&P 500 has barely moved in 2025, gaining only 1.5%, and has risen 17% over the past year.

Yet, as the allure of the precious metal intensifies, seasoned investors are urging restraint. Certified financial planner Lee Baker of Claris Financial Advisors recalls, “I didn’t get any calls from clients about gold a year ago. Now, I get them regularly.” He cites Warren Buffett’s timeless advice: “Be cautious when others are greedy, and be greedy when others are fearful.” Baker warns that while the current fervor is tempting, the typical investor should limit gold allocation to no more than 3% of a diversified portfolio—lest they fall into the classic trap of buying high and selling low.

Why are gold prices on the rise? The answer lies in its enduring reputation as a safe haven during turbulent times. Investors flock to gold amid uncertainty, with recent US sanctions against Russia acting as a turbocharger for returns. These sanctions have spurred central banks, particularly in China, to boost their gold purchases instead of U.S. Treasury bonds, aiming to safeguard their reserves from potential geopolitical strife. Moreover, many see gold as a hedge against inflation, even though the data supporting that view remains mixed.

Samir Samana, senior global market strategist at Wells Fargo Investment Institute, notes, “In times of real crisis, bonds have shone brighter than gold.” His perspective underscores that while gold may shine during periods of high uncertainty, its rally might be unsustainable without a prolonged crisis.

For investors, the takeaway is clear: while gold’s current surge offers attractive returns, caution is paramount. As the market faces potential headwinds, following Buffett’s contrarian wisdom may help avoid the pitfalls of an overheated market. In the world of investing, where timing is everything, it’s not just about chasing returns—it’s about staying disciplined when the herd runs wild.

Reid Hoffman Leaves Microsoft Board To Focus On Manus AI

Former Microsoft board member Reid Hoffman has stepped down from the company’s board, marking a return to startup building and investment activities. Hoffman joined Microsoft’s board following the company’s $26.2 billion acquisition of LinkedIn in 2016.

Strategic Investment And Board Leadership

During his time on the board, Hoffman was involved in a period of significant investment in artificial intelligence, including Microsoft’s first $1 billion investment in OpenAI in 2019. As an early investor in OpenAI, Hoffman also served on the organisation’s board before stepping down in 2023 to avoid potential conflicts of interest.

Acqui-Hire Deals And AI Synergies

Hoffman’s board tenure coincided with significant strategic moves, including Microsoft’s $650 million acqui-hire deal involving his AI startup, Inflection AI. This arrangement, which saw Microsoft adding Inflection co-founder Mustafa Suleyman to its ranks, highlights the increasingly blurred lines between corporate reinvention and startup innovation in the tech landscape.

Return to Founder Mode With Manus AI

In a recent conversation on his “Possible” podcast with Microsoft CEO Satya Nadella, Hoffman revealed his excitement to return to “founder mode” with his latest venture, Manus. This AI-driven drug discovery startup has already raised over $50 million through early seed rounds, marking it as a promising player in the competitive field of AI in healthcare.

Leadership Under Visionary Guidance

Hoffman serves as co-founder and chair of Manus AI. Day-to-day leadership is led by Dr. Siddhartha Mukherjee, a physician, biologist and Pulitzer Prize-winning author of The Emperor of All Maladies: A Biography of Cancer. The company is focused on applying artificial intelligence to chemistry and drug discovery, including research related to cancer treatment. Hoffman’s departure from Microsoft’s board comes as he increases his focus on new ventures in artificial intelligence and healthcare.

Aretilaw firm
Uol
The Future Forbes Realty Global Properties
eCredo

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter